Cluenex
Log inStart free
All stocks · Healthcare · Health Care Services

Labcorp LH

Labcorp scores weak on business quality (4.5 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$312.15Oct 9, 2026
Business qualityWeak
Next earningsOct 28, 2026
Insiders, 90 daysSelling

Why it matters

  1. What Labcorp does

    Labcorp Holdings operates diagnostic laboratories, generating revenue by processing clinical lab tests for hospitals, physicians, and patients.

  2. What it does best

    Labcorp excels in diagnostic scale, producing $14.3 billion in revenue with a gross margin of 28.9%. This edges out peer CVS at 14.2% and peer CI at 9.1%, though competitor DGX commands a higher gross margin of 33.2%.

  3. The main risk

    With net debt of $5.1 billion, the company carries significant leverage that limits financial flexibility if diagnostic volumes falter or operational costs rise unexpectedly.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityWeak

Operating margin stands at 11.4% with a net margin of 7.0%, reflecting stable conversion of its $14.3 billion revenue base into bottom-line earnings.

MoatWeak

Its network of testing facilities anchors a medical provider lock-in, placing its gross margin in the bottom decile of its sector due to high fixed lab costs.

GrowthSlow

Revenue grew 7.2% to $14.3 billion over the latest period, showing a steady expansion following historical periods of post-pandemic normalization.

Financial healthFair

Debt-to-equity sits at 0.7 with interest coverage at 7.2x, supported by $1.2 billion in free cash flow. The balance sheet is holding steady.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

2 sold $723K outside pre-planned sales.

Our sealed record on LH

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is LH a good business?

Labcorp scores weak on the Cluenex quality check (4.5 of 10), measured against its own industry. Profitability is weak, moat weak, growth slow and financial health fair.

Are insiders buying LH?

In the last 90 days of SEC Form 4 filings: 2 sold $723K outside pre-planned sales.

When does LH report earnings?

Oct 28, 2026.

For members

See LH today

  • Today's verdict on LH, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Labcorp (LH)”, https://cluenex.com/stocks/lh/, data as of Oct 10, 2026.